Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2007
05/17/2007US20070112032 Prevention and/or reduction of photoreceptor degeneration with retinoids
05/17/2007US20070112031 Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
05/17/2007US20070112030 Processes for preparing bicyclo [3.1.0] hexane derivatives, and intermediates thereto
05/17/2007US20070112029 Piperidine compound and process for preparing the same
05/17/2007US20070112028 2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
05/17/2007US20070112027 Crystalline forms of a biphenyl compound
05/17/2007US20070112026 Carbostyril derivatives for accelerating salivation
05/17/2007US20070112025 Use of kynurenine-3-hydroxylase inhibitors for the preparation of medicaments for the treatment of l-dopa induced movement disorders, dyskinesias, drug addiction, pain and cataract
05/17/2007US20070112024 Crystal form of quinoline compound and process for its production
05/17/2007US20070112023 (3R)-N-(4'-Aminobiphenyl-4-yl)quinuclidine-3-carboxamide dihydrochloride; nicotinic acetylcholine receptors of alpha7 subtype agonist; high permeability for calcium ions, increases glutamatergic neurotransmission, modulates neuronal plasticity; cognition activator, leaning and perception inhancement
05/17/2007US20070112022 Piperidine derivatives as ccr5 receptor modulators
05/17/2007US20070112021 Inhibiting gastric acid secretion
05/17/2007US20070112020 5Z)-2-(3-methylphenyl)-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethylene)-3,5-dihydro-4H-imidazol-4-one; treating diseases linked to disregulated cell proliferation or to disregulated protein kinase
05/17/2007US20070112019 9-Azabicyclo[3.3.1]nonane derivatives
05/17/2007US20070112018 Treatment of peripheral arterial occlusive disease
05/17/2007US20070112017 Gaba receptor mediated modulation of neurogenesis
05/17/2007US20070112016 1-((tetrahydropyran-2-yl)oxy-ethyl)-5-tert-butoxycarbonyl-spiro[indoline-3,4'-piperidin]-2-one; ORL-1 (orphan opioid receptor) G-protein coupled receptor; brain, psychological disorders
05/17/2007US20070112015 Substituted dihydropyridines and methods of use
05/17/2007US20070112014 Therapeutic Compounds Based on Pyrazolopyridine
05/17/2007US20070112013 Method of modulating ion channel functional activity
05/17/2007US20070112012 Carbocyclic fused cyclic amines
05/17/2007US20070112011 Substituted 1-propiolylpiperazine compounds, their preparation and use
05/17/2007US20070112010 Use of pde iii inhibitors for the treament of asymptomatic (occult) heart failure
05/17/2007US20070112009 1-N-phenyl-amino-1h-imidazole derivatives and pharmaceutical compositions containing them
05/17/2007US20070112008 Saframycins, analogues and uses thereof
05/17/2007US20070112007 Cyclohexyl-1, 4-diamine compounds
05/17/2007US20070112006 such as (7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4yloxy)phenyl]amine, used as tyrosine kinase inhibitors for the treatment of tumors
05/17/2007US20070112005 Fused bicyclic mTOR inhibitors
05/17/2007US20070112004 such as 2-chloro-9-(4-thio-alpha-L-xylofuranosyl)adenine for treatment of leukemia; anticancer agents
05/17/2007US20070112003 3-(3-Amino-4-chloro-phenyl)-5-(3-chlorothiophen-2-yl)-[1,2,4]-oxadiazole; anticancer agents; coadministering with other chemotherapeutics or radiotherapy
05/17/2007US20070112002 1-[2-(4,4-dimethylcyclohexyl)-5-methoxyphenyl]-4-pentylpiperazine; excellent cell adhesion inhibitory action or cell infiltration inhibitory action; inflammatory diseases and autoimmune diseases such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, rheumatoid arthritis, psoriasis, asthma
05/17/2007US20070112001 Treatment of thrombotic disorders, such as arterial and venous thrombosis, peripheral arterial occlusive disease, angina pectoris, myocardial infarction; (2S,4S)-4-[(5-chloro-thiophene-2-carbonyl)-amino]2-[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenylcarbamoyl]-pyrrolidine-1-carboxylic acid tert-butyl ester
05/17/2007US20070112000 Chemical compounds
05/17/2007US20070111999 P-38 kinase inhibitors
05/17/2007US20070111998 Novel heterocyclic compounds as pSTAT3/IL-6 inhibitors
05/17/2007US20070111997 Triazolopyrimidines and related analogs as HSP90-inhibitors
05/17/2007US20070111996 Pyrazolopyrimidines and related analogs as HSP90-inhibitors
05/17/2007US20070111995 Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors
05/17/2007US20070111994 Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
05/17/2007US20070111993 Pharmaceutical composition comprising a salt of mirtazapine
05/17/2007US20070111992 Cathepsin K and cathepsin S dependent disorders such as osteoporosis, atherosclerosis, inflammation and immune disorders such as rheumatoid arthritis and chronic pain; e.g. 4-(piperazin-1-yl)-6-(3-trifluoromethylphenyl)-pyrimidine-2-carbonitrile
05/17/2007US20070111991 10,11-Dihydro-dibenzo[b,f]oxepine-10-carboxylic acid [(1S*,2S*,4R*)-4-butylcarbamoyl-2-hydroxy-1-(3-hydroxy-benzyl)-pentyl]-amide; treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
05/17/2007US20070111990 3-Aza-1-oxa-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
05/17/2007US20070111989 Novel diazabicyclononene derivatives and use
05/17/2007US20070111988 Selective estrogen receptor modulators
05/17/2007US20070111987 cyclization using phosphorus oxychloride; antipsychotic or neuroleptic agent for psychological disorders
05/17/2007US20070111986 comprises the ring closure and deprotection of an intermediate; 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f]-1,4-thiazepine; used as an antipsychotic or neuroleptic
05/17/2007US20070111985 HIV integrase inhibitors
05/17/2007US20070111984 HIV integrase inhibitors
05/17/2007US20070111983 Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
05/17/2007US20070111982 Calcitonin Gene-Related Peptide, CGRP; treatment of migraine and cluster headache; 2,5-dioxo-3',4'-dihydro-spiro(imidazolidine-4,2'(1'H)-naphthalene)-6'-carboxamides
05/17/2007US20070111981 New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
05/17/2007US20070111980 Process for preparing pure cephalosporine intermediates
05/17/2007US20070111979 Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule
05/17/2007US20070111978 Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
05/17/2007US20070111977 Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
05/17/2007US20070111976 Method of preventive on-demand hormonal contraception
05/17/2007US20070111975 Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
05/17/2007US20070111974 Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
05/17/2007US20070111973 Treatment of tumours
05/17/2007US20070111972 "methods and products for treatment of diseases"
05/17/2007US20070111971 Novel compounds
05/17/2007US20070111970 Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence
05/17/2007US20070111969 Pharmaceutical compositions for the administration of aptamers
05/17/2007US20070111968 1-Aza-dibenzo[e,h]azulenes for the treatment of central nervous system diseases and disorders
05/17/2007US20070111967 Organosilicon compounds and their use
05/17/2007US20070111966 Method for the treatment and/or prevention of urinary disorders
05/17/2007US20070111965 Compositions comprising lipoxygenase inhibitors and cyclodextrin
05/17/2007US20070111964 Vitamin B12 nasal spray and method of use
05/17/2007US20070111961 Dbait and uses thereof
05/17/2007US20070111960 High affinity probes for analysis of human papillomavirus expression
05/17/2007US20070111956 Remedy for sarcoidosis and method of treating the same
05/17/2007US20070111955 Extraction and purification method of active constituents from stem of Lonicera japonica Thunb., its usage for anti-inflammatory and analgesic drug
05/17/2007US20070111954 Apparatus and method of wart treatment
05/17/2007US20070111953 Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for treatment of cardiovascular disease
05/17/2007US20070111952 Glycosylated triketide delta lactones
05/17/2007US20070111951 Novel galactosylceramide analogues, and beta-glucocerebrosidase activator, external skin preparations and method of activating beta-glucocerebrosidase using the same
05/17/2007US20070111950 Indole compounds useful for the treatment of cancer
05/17/2007US20070111949 Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors
05/17/2007US20070111936 Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
05/17/2007US20070111915 mixture of sodium thiocyanate, sodium iodide, periodic acid, water, monoethylenically unsaturated monomers containing nitrogen and/or phosphorous containing groups ( e.g. vinyl pyrrolidone, vinyl imidazole, acrylamide, vinyl phosphonic acid), optional other comonomer, crosslinker; shelf-life
05/17/2007US20070111292 Structured lipid mixtures
05/17/2007US20070111265 Ligands for mineralocorticoid receptor (MR) and methods for screening for or designing MR ligands
05/17/2007US20070111263 Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase c regulation
05/17/2007US20070111191 Storage of blood
05/17/2007US20070110834 Composition comprising the alcohol compound isolated from the extract of cucurbitaceae family plant having anti-adipogenic and anti-obesity activity
05/17/2007US20070110829 Process for metabolic control and high solute clearance and solutions for use therein
05/17/2007US20070110828 Administering a NF- kappa B inhibitor in conjunction with the administration of a chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased
05/17/2007US20070110827 Pharmaceutical compositions for the administration of aptamers
05/17/2007US20070110826 Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
05/17/2007US20070110819 Composite structures containing hyaluronic acid the derivatives thereof as new bone substitutes and grafts
05/17/2007US20070110815 Micronised azodicarbonamide, and the preparation and use thereof
05/17/2007US20070110812 Ophthalmic composition for dry eye therapy
05/17/2007US20070110808 Extended release osmo-microsealed formulation
05/17/2007US20070110807 Delayed release tablet with defined core geometry
05/17/2007US20070110806 Core contains acid-unstable drug and disintegrant, and release-controlling coating contains water-insoluble polymer, an enteric polymer and hydrophobic wax; capsules
05/17/2007US20070110805 Modified-release pharmaceutical compositions
05/17/2007US20070110804 Drug polymer complexes
05/17/2007US20070110803 Pharmaceutical formulation comprising levothyroxine sodium
05/17/2007US20070110801 Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method